Drug therapy for chronic asthma in children

Archives of Disease in Childhood: Education and Practice Edition

Volumn 95, Issue 5, 2010, Pages 145-150

  Anderson, Mark ^a   Thomas, David A ^b  

^a DERBYSHIRE CHILDREN S HOSPITAL   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE; FORMOTEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; OMALIZUMAB; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE;

ADRENAL SUPPRESSION; AEROSOL; ANOREXIA; ASTHMA; CHRONIC DISEASE; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; GROWTH DISORDER; HEADACHE; HUMAN; IMMUNOTHERAPY; INHALATION SPACER; METERED DOSE INHALER; NAUSEA; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SLEEP DISORDER; TACHYPHYLAXIS;

ALGORITHMS; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CHRONIC DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PEDIATRICS;

EID: 77957361819     PISSN: 17430585     EISSN: 17430593     Source Type: Journal    
DOI: 10.1136/adc.2008.153460     Document Type: Review

References (74)

1. Robertson CF, Heycock E, Bishop J, et al. Prevalence of asthma in Melbourne schoolchildren: changes over 26 years. BMJ 1991;302:1116-18.
2. Peat JK, van den Berg RH, Green WF, et al. Changing prevalence of asthma in Australian children. BMJ 1994;308:1591-6.
3. Anderson HR, Butland BK, Strachan DP. Trends in prevalence and severity of childhood asthma. BMJ 1994;308:1600-4.
4. Sunderland RS, Fleming DM. Continuing decline in acute asthma episodes in the community. Arch Dis Child 2004;89:282-5.
5. Masoli M, Fabian D, Holt S, et al; Global Initiative for Asthma (GINA) program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469-78.
6. European lung white book. 2003 European Respiratory Society and the European Lung Foundation. Brussels, Belgium.
7. Everhart RS, Fiese BH. Asthma severity and child quality of life in pediatric asthma: a systematic review. Patient Educ Couns 2009;75:162-8.
8. Warner JO, Götz M, Landau LI, et al. Management of asthma: a consensus statement. Arch Dis Child 1989;64:1065-79.
9. Borish L, Culp JA. Asthma: a syndrome composed of heterogeneous diseases. Ann Allergy Asthma Immunol 2008;101:1-8; quiz 8-11, 50.
10. Sharma S, Litonjua AA, Tantisira KG, et al.; Childhood Asthma Management Program Research Group. Clinical predictors and outcomes of consistent bronchodilator response in the childhood asthma management program. J Allergy Clin Immunol 2008;122:921-928.e4.
11. Lipworth BJ. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax 1995;50:105-10.
12. National Institute for Clinical Excellence. Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma. London: NICE, 2000.
13. National Institute for Clinical Excellence. Inhaler devices for routine treatment of chronic asthma in older children (5-15 years). London: NICE, 2002.
14. Newman SP, Newhouse MT. Effect of add-on devices for aerosol drug delivery: deposition studies and clinical aspects. J Aerosol Med 1996;9:55-70.
15. Barry PW, O'Callaghan C. Inhalational drug delivery from seven different spacer devices. Thorax 1996;51:835-40.
16. Mitchell JP, Nagel MW, Rau JL. Performance of large volume vs small volume holding chambers chlorofluorocarbon albuterol and hydrofluoroalkane albuterol sulphate. Respir Care 1999;44:38-44.
17. Cheng NG, Browne GJ, Lam LT, et al. Spacer compliance after discharge following a mild to moderate asthma attack. Arch Dis Child 2002;87:302-5.
18. Janssens HM, Devadason SG, Hop WC, et al. Variability of aerosol delivery via spacer devices in young asthmatic children in daily life. Eur Respir J 1999;13:787-91.
19. Barry PW, O'Callaghan C. The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler. Br J Clin Pharmacol 1995;40:76-8.
20. Wildhaber JH, Devadason SG, Hayden MJ, et al. Electrostatic charge on a plastic spacer device influences the delivery of salbutamol. Eur Respir J 1996;9:1943-6.
21. Iles R, Lister P, Edmunds AT. Crying significantly reduces absorption of aerosolised drug in infants. Arch Dis Child 1999;81:163-5.
22. Janssens HM, van der Wiel EC, Verbraak AF, et al. Aerosol therapy and the fighting toddler: is administration during sleep an alternative? J Aerosol Med 2003;16:395-400.
23. Esposito-Festen J, Ijsselstijn H, Hop W, et al. Aerosol therapy by pressured metered-dose inhaler-spacer in sleeping young children: to do or not to do? Chest 2006;130:487-92.
24. Haughney J, Price D, Kaplan A, et al. Achieving asthma control in practice: understanding the reasons for poor control. Respir Med 2008;102:1681-93.
25. Hagmolen of ten Have W, van de Berg NJ, Bindels PJ, et al. Assessment of inhalation technique in children in general practice: increased risk of incorrect performance with new device. J Asthma 2008;45:67-71.
26. Munzenberger PJ, Thomas R, Bahrainwala A. Retention by children of device technique for inhaled asthma drugs between visits. J Asthma 2007;44:769-73.
27. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000;343:332-6.
28. British Thoracic Society Scottish Intercollegiate Guidelines Network. 2008 British Guideline on the Management of Asthma - updated June 2009. http://www.brit-thoracic.org. uk/ClinicalInformation/Asthma/AsthmaGuidelines/ tabid/83/Default.aspx. Accessed 1 November 2009.
29. Adcock IM, Lane SJ. Corticosteroid-insensitive asthma: molecular mechanisms. J Endocrinol 2003;178:347-55.
30. Adams N, Lasserson TJ, Cates CJ, et al. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev 2007;4:CD002310.
31. Adams NP, Bestall JB, Malouf R, et al. Inhaled beclomethasone versus placebo for chronic asthma. Cochrane Database Syst Rev 2005;3:CD002738.
32. Adams NP, Bestall JC, Jones P. Budesonide versus placebo for chronic asthma in children and adults. Cochrane Database Syst Rev 1999;4:CD003274.
33. Adams NP, Bestall JC, Lasserson TJ, et al. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database Syst Rev 2008;4:CD003135.
34. Adams NP, Jones PW. The dose-response characteristics of inhaled corticosteroids when used to treat asthma: an overview of Cochrane systematic reviews. Respir Med 2006;100:1297-306.
35. Main C, Shepherd J, Anderson R, et al. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years. Health Technol Assess 2008;12:1-174, iii-iv.
36. Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005;115:233-42.
37. Rachelefsky G. Inhaled corticosteroids and asthma control in children: assessing impairment and risk. Pediatrics 2009;123:353-66.
38. Gulliver T, Morton R, Eid N. Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. Paediatr Drugs 2007;9:185-94.
39. Todd GR, Acerini CL, Ross-Russell R, et al. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002;87:457-61.
40. Shepherd GL, Hetzel MR, Clark TJ. Regular versus symptomatic aerosol bronchodilator treatment of asthma. Br J Dis Chest 1981;75:215-7.
41. Walters EH, Walters J, Gibson PG, et al. Inhaled short acting beta2-agonist use in chronic asthma: regular versus as needed treatment. Cochrane Database Syst Rev 2003;1:CD001285.
42. Tattersfield AE. Clinical pharmacology of long-acting beta-receptor agonists. Life Sci 1993;52:2161-9.
43. van Noord JA, Smeets JJ, Raaijmakers JA, et al. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996;9:1684-8.
44. Anderson GP. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. Life Sci 1993;52:2145-60.
45. Johnson M, Butchers PR, Coleman RA, et al. The pharmacology of salmeterol. Life Sci 1993;52:2131-43.
46. Green SA, Spasoff AP, Coleman RA, et al. Sustained activation of a G protein-coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor. J Biol Chem 1996;271:24029-35.
47. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26.
48. Sears MR, Lötvall J. Past, present and future - beta2- adrenoceptor agonists in asthma management. Respir Med 2005;99:152-70.
49. Carroll WD, Jones PW, Boit P, et al. Childhood evaluation of salmeterol tolerance-A double-blind randomized controlled trial. Pediatr Allergy Immunol 2010;21:336-44.
50. Rodrigo GJ, Moral VP, Marcos LG, et al. Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review. Pulm Pharmacol Ther 2009;22:9-19.
51. Global Strategy for Asthma Management and Prevention 2008. The Global Initiative for Asthma 2008. http://www.ginasthma.com/Guidelineitem.asp??l1= 2&l2=1&intId=1561. Accessed 1 November 2009.
52. Ni Chroinin M, Greenstone IR, Danish A, et al. Longacting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst Rev 2005;4:CD005535.
53. Gappa M, Zachgo W, von Berg A, et al.; VIAPAED Study Group. Add-on salmeterol compared to double dose fluticasone in pediatric asthma: a double-blind, randomized trial (VIAPAED). Pediatr Pulmonol 2009;44:1132-42.
54. de Blic J, Ogorodova L, Klink R, et al. Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children. Pediatr Allergy Immunol 2009;20:763-71.
55. Cates CJ, Lasserson TJ. Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children. Cochrane Database Syst Rev 2009;1:CD007085.
56. Bisgaard H, Le Roux P, Bjåmer D, et al. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest 2006;130:1733-43.
57. Alton EW, Norris AA. Chloride transport and the actions of nedocromil sodium and cromolyn sodium in asthma. J Allergy Clin Immunol 1996;98:S102-5; discussion S105-6.
58. Guevara JP, Ducharme FM, Keren R, et al. Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma. Cochrane Database Syst Rev 2006;2:CD003558.
59. van der Wouden JC, Uijen JH, Bernsen RM, et al. Inhaled sodium cromoglycate for asthma in children. Cochrane Database Syst Rev 2008;4:CD002173.
60. Dahlén SE. Treatment of asthma with antileukotrienes: first line or last resort therapy? Eur J Pharmacol 2006;533:40-56.
61. Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001;108:E48.
62. van Adelsberg J, Moy J, Wei LX, et al. Safety, tolerability, and exploratory efficacy of montelukast in 6- to 24-month-old patients with asthma. Curr Med Res Opin 2005;21:971-9.
63. Simons FE, Villa JR, Lee BW, et al. Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. J Pediatr 2001;138:694-8.
64. Knuffman JE, Sorkness CA, Lemanske RF Jr, et al. Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma. J Allergy Clin Immunol 2009;123:411-16.
65. NIHR Health Technology Assessment Programme. http://www.hta.ac.uk/1599. Accessed 7 May 2009.
66. Fredholm BB. On the mechanism of action of theophylline and caffeine. Acta Med Scand 1985;217:149-53.
67. Adcock IM, Ito K, Barnes PJ. Histone deacetylation: an important mechanism in inflammatory lung diseases. COPD 2005;2:445-55.
68. Seddon P, Bara A, Ducharme FM, et al. Oral xanthines as maintenance treatment for asthma in children. Cochrane Database Syst Rev 2006;1:CD002885.
69. Kondo N, Katsunuma T, Odajima Y, et al. A randomized openlabel comparative study of montelukast versus theophylline added to inhaled corticosteroid in asthmatic children. Allergol Int 2006;55:287-93.
70. Skoner DP. Balancing safety and efficacy in pediatric asthma management. Pediatrics 2002;109:381-92.
71. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108:E36.
72. Ponsonby AL, Gatenby P, Glasgow N, et al. Which clinical subgroups within the spectrum of child asthma are attributable to atopy? Chest 2002;121:135-42.
73. Penagos M, Passalacqua G, Compalati E, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008;133:599-609.
74. Möller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109:251-6.